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Summary
The recently completed European trial of interferon beta- had a greater reduction of cerebral volume in the placebo
group (mean reduction at month 36: placebo 5.1%, IFNβ- 1b (IFNβ-1b) in patients with secondary progressive
1b 1.8%, P < 0.05) whereas those with Gd-enhancing multiple sclerosis (SP multiple sclerosis) has given an
lesions showed a trend to greater reduction of cerebral opportunity to assess the impact of treatment on cerebral
volume if the patient was on IFNβ-1b (placebo 2.6%, atrophy using serial MRI. Unenhanced T1-weighted brain
IFNβ-1b 3.7%; P > 0.05). These results are consistent imaging was acquired in a subgroup of 95 patients from
with ongoing tissue loss in both arms of this study of ﬁve of the European centres; imaging was performed at
secondary progressive multiple sclerosis. This ﬁnding 6-month intervals from month 0 to month 36. A blinded
is concordant with previous observations that disease observer measured cerebral volume on four contiguous
progression, although delayed, is not halted by IFNβ. The
5 mm cerebral hemisphere slices at each time point, using differentpatternseeninpatientswithandwithoutbaseline
an algorithm with a high level of reproducibility and gadoliniumenhancementsuggeststhatpartofthecerebral
automation. There was a signiﬁcant and progressive volume reduction observed in IFNβ-treated patients may
reduction in cerebral volume in both placebo and treated be due to the anti-inﬂammatory/antioedematous effect of
groups, with a mean reduction of 3.9 and 2.9%, the drug. Longer periods of observation and larger groups
respectively, by month 36 (P  0.34 between groups). of patients may be needed to detect the effects of treatment
Exploratory subgroup analyses indicated that patients on cerebral atrophy in this population of patients with
advanced disease without gadolinium (Gd) enhancement at the baseline
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Abbreviations: EDSS  expanded disability status scale; IFNβ-1b  interferon beta-1b; RR  relapsing–remitting; SP 
secondary progressive
Introduction
The recently published trial of interferon beta-1b (IFNβ-1b) T2 lesion volume in the treated group after 3 years (Miller
et al., 1999). This disparity between the magnitude of the in secondary progressive (SP) multiple sclerosis demonstrated
a highly signiﬁcant effect of treatment on the primary clinical treatment effect on MRI and clinical indices has also been
noted in a number of other recent phase III studies in earlier outcome—delay of conﬁrmed disability progression—as well
as on relapse-related parameters (European Study Group, relapsing–remitting (RR) multiple sclerosis (IFNβ Study
Group, 1995, PRISMS Study Group, 1998). Consequently, 1998). However, the treatment effect on the primary MRI
outcomes was considerably greater: a reduction in monthly appropriate concerns have been raised about the utility of
such MRI indices as outcome measures in multiple sclerosis gadolinium-enhancing lesion activity of up to 80% was found
on treatment, in association with complete stabilization of treatment trials (Miller et al., 1998).
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The limited nature of the correlation between clinical the most caudal at the level of the velum interpositum cerebri,
as this was found to be the most reproducible method progression, assessed with the Expanded Disability Status
Scale (EDSS) and the change in T2 lesion volume, has also covering the region of interest. Next, the algorithm was
applied slice by slice, with subsequent review of the been reported in a number of recent studies (Paty et al.,
1993; Molyneux et al., 1998). This is likely to reﬂect the effectiveness of the extraction process. In a small percentage
of slices, the extraction was incomplete, resulting in residual low pathological speciﬁcity of standard T2-weighted imaging
for the more destructive pathological elements of small islands of skull, and these non-brain regions were
manually deleted where necessary. demyelination and axonal loss, and makes caution advisable
in the interpretation of T2 lesion volume ﬁndings in isolation. Following extraction and editing, the volume of the
extracted brain in the four slices was calculated with in- Several novel MRI techniques have been developed
recently that offer the prospect of selectively monitoring house software (Calc-Vol; L. Wang, Institute of Neurology,
University College London, London, UK). Progressive different aspects of the disease process. The European IFNβ-
1b trial in SP multiple sclerosis has provided the opportunity atrophy was expressed as change in millilitres per year.
For the serial MRI studies of each patient, each study to apply a number of these MRI tools in a large phase III
study. In particular, serial measurements of cerebral volume was compared against the baseline image to ensure that
repositioning was adequate. When this was not the case, that have been performed in a subgroup of patients in this study,
giving an opportunity to study the effect of IFNβ-1b treatment image was excluded from the analysis.
on tissue loss in patients with SP multiple sclerosis. The
present paper reports the results of this analysis.
Statistical analysis
Comparison between baseline cerebral volumes as deﬁned
(i.e. the four contiguous slices rostral to the velum Methods
Seven hundred and eighteen patients with SP multiple interpositum)intheplaceboandtreatedgroupswasperformed
using the Wilcoxon rank sum test. The signiﬁcance of any sclerosis were recruited from 32 European centres into a
randomized, double-blind, placebo-controlled trial of IFNβ- within-group change in cerebral volume from baseline was
assessed using a paired t-test for both the placebo and the 1b planned to occupy 3 years. The trial design, the major
clinical endpoints and the core MRI protocol have been treatedpatients.Thisanalysiswasperformedforbothabsolute
and percentage change in the MRI variables. Statistical described elsewhere (Polman et al., 1995; European Study
Group 1998). In addition to the annual imaging, a subgroup analyses included all data available at a given time, with
missing data maintained as missing. In addition, cerebral of 95 patients from ﬁve of the 32 European centres underwent
T1-weighted brain imaging at intervals of 6 months; from volumes at individual last visits (last scan available) were
evaluated for all patients who had data available at least once these images an assessment of tissue loss was performed
using methods described below. during treatment.
Non-parametric analysis of covariance with stratiﬁcation
adjustment for centre and covariance adjustment for baseline
cerebral volume was used to assess the signiﬁcance of any MRI acquisition
The brain MRI protocol comprised an unenhanced treatment effect on cerebral volume at each time point. Post
hoc analysis was performed by stratifying patients into those T1-weighted spin-echo (SE) sequence with the following
parameters: TR (repetition time)  500–700 ms; TE (echo with and those without gadolinium enhancement at the
baseline and subsequently repeating the analysis. However, time) 5–25 ms; ﬁeld of view 25 cm; 28 axial oblique,
contiguous, interleaved 5 mm slices; matrix 256  256; 1 since sample sizes are small in the subgroups of patients
with and without gadolinium enhancement at the baseline, or 2 excitations. This protocol was performed at baseline and
thenatintervalsof6monthsuntilmonth36;repositioningwas consideration of centres might not be appropriate. Thus,
non-parametric analyses of covariance with adjustment for performed with a protocol based on standardized anatomical
landmarks (Gallagher et al., 1997). baseline cerebral volume alone were used to explore
associations between treatment and percentage change from
baseline in cerebral volume. In addition, a repeated measures
analysis of variance was performed to further investigate MRI analysis
Measurement of cerebral volume was performed by a single the signiﬁcance of any treatment effect over the whole
study duration. blinded observer using an automated algorithm that ﬁrst
extracted the brain from the skull and CSF spaces, and then The strength of the relationship between the MRI data
and two clinical variables—(i) EDSS and (ii) a composite quantiﬁed the volume of the extracted image. Details of the
algorithm have been described fully (Losseff et al., 1996). neuropsychological change score (Rao et al., 1991)—was
assessed with Goodman–Kruskal correlation coefﬁcients. This approach was highly reproducible, with a mean scan–
rescan coefﬁcient of variation of 1%. The analysis process The composite neuropsychological change score measured
sustained attention and concentration, verbal learning and required an observer to select four contiguous slices, with2258 P. D. Molyneux et al.
Table 1 Baseline demographic and disease characteristics of cohort as a whole (n  718) and subgroups evaluated for
cerebral volume (n  95)
Placebo IFNβ-1b
Baseline variable Cohort Subgroup Cohort Subgroup
(n  358) (n  46) (n  360) (n  49)
Female (%) 64.2* 43.5 58.1 53.1
Age (years) Mean 40.9 39.6 41.1 40.3
SD 7.9 8.6 7.7 8.9
Disease duration (years) Mean 13.4 13.1 12.8 10.9
SD 7.5 6.7 6.6 6.4
Time since evidence of Mean 3.8 4.1* 3.8 3.2
progressive deterioration (years) SD 3.4 2.6 2.7 2.0
Time since diagnosis of Mean 2.1 2.1 2.2 1.4
SP multiple sclerosis (years) SD 2.2 1.9 2.3 1.2
Baseline EDSS Mean 5.2 5.3* 5.1 4.9
SD 1.1 1.0 1.1 1.1
EDSS 3.5 n (%) 47 (13.1) 4 (8.7) 67 (18.6) 11 (22.4)
EDSS 4–5.5 n (%) 142 (39.7) 18 (39.1) 140 (38.9) 24 (49.0)
EDSS 6.0 n (%) 169 (47.2) 24 (52.2)† 153 (42.5) 14 (28.6)
T2 lesion volume (cm3) Mean 28.4 28.3 26.6 26.2
SD 22.5 20.7 21.2 23.6
Number of enhancing lesions
Mean 2.2 2.3 3.0 2.5
SD 3.8 3.7 6.6 5.0
*P  0.10 between treatment groups within cohort or subgroup; †P  0.05 between treatment groups within cohort or subgroup.
delayed recall, visuospatial learning and delayed recall, and
semantic retrieval(Rao etal., 1991).The relationshipbetween
cerebral volume and the primary MRI variables from the
study (T2 lesion volume and new lesion activity) was also
assessed with Goodman–Kruskal correlation coefﬁcients.
Results
Patients (Table 1)
The placebo and treated groups were well matched for
baseline cerebral volume as deﬁned (307 and 308 cm3 in Fig. 1 Percentage change in cerebral volume compared with
placebo and treated groups, respectively; P  0.90), and for baseline for all patients.
age, duration of multiple sclerosis, number of enhancing
lesions, T2 lesion volume, and EDSS change and number of
relapses in the 2 years before the study. The time since Of the 95 patients recruited into the cerebral atrophy
protocol, 65 had cerebral volume measured at month 36. The evidence of progressive deterioration and diagnosis of SP
multiple sclerosis was longer and EDSS scores were higher dropouts reﬂect a combination of (i) patients who dropped
out of the entire study, or just the imaging protocol (n 20), in the placebo group (P  0.01), and the proportion of
patients with higher EDSS scores was signiﬁcantly greater and (ii) MRI studies that were rejected due to inadequate
repositioning (n  10). in the placebo than the IFNβ-1b group (P  0.05); none of
these group differences was seen in the study cohort as a
whole (European Study Group, 1998). In the present
subgroup, 43.5% of the patients on placebo were female Cerebral volume
The changes in cerebral volume over the study duration compared with 53.1% of the patients on IFNβ-1b; this is in
contrast to the study cohort as a whole, in which according to treatment effect are given in Table 2 and Fig. 1.
In the placebo group, a signiﬁcant 0.89% mean reduction in approximately 60% of patients in both groups were female.Cerebral atrophy 2259
Table 2 Percentage change in cerebral volume from Table 3 Percentage change in cerebral volume from
baseline: patients without gadolinium enhancement at baseline
baseline
Placebo IFNβ-1b P*
Placebo IFNβ-1b P*
Baseline volume
n† 44 48 Baseline volume
Mean (SD) 307.26 (26.97) 308.25 (25.71) n 22 21
Median 309.76 308.21 0.9067 Mean (SD) 305.13 (28.64) 309.80 (29.17)
Median 302.10 305.05 0.5763 Percentage change in cerebral volume from baseline
Month 6 Percentage change in cerebral volume from baseline
n 34 39 Month 6
Mean (SD) –0.89 (1.35) –1.39 (1.47) n 16 16
Median –0.76 –1.29 Mean (SD) –0.67 (1.67) –0.96 (1.34)
P‡ 0.0005 0.0001 0.0896 Median –0.48 –0.94
Month 12 P† 0.1297 0.0117 0.6689
n 38 39 Month 12
Mean (SD) –1.40 (1.69) –1.60 (2.50) n 18 16
Median –1.51 –0.82 Mean (SD) –1.52 (1.99) –1.72 (1.73)
P‡ 0.0001 0.0002 0.3014 Median –1.50 0.03
Month 18 P† 0.0048 0.1150 0.1476
n 38 37 Month 18
Mean (SD) –2.02 (2.83) –1.65 (2.34) n 20 17
Median –1.68 –1.32 Mean (SD) –2.29 (3.19) –1.15 (1.46)
P‡ 0.0001 0.0001 0.6498 Median –1.80 –0.96
Month 24 P† 0.0045 0.0049 0.2806
n 33 39 Month 24
Mean (SD) –2.76 (3.30) –2.17 (2.90) n 17 17
Median –2.27 –1.75 Mean (SD) –3.09 (3.77) –1.45 (1.72)
P‡ 0.0001 0.0001 0.1612 Median –2.27 –1.61
Month 30 P† 0.0038 0.0031 0.2741
n 29 31 Month 30
Mean (SD) –2.74 (3.38) –2.84 (3.12) n 15 14
Median –2.21 –2.68 Mean (SD) –3.47 (3.77) –2.08 (1.65)
P‡ 0.0001 0.0001 0.4388 Median –2.21 –2.13
Month 36 P† 0.0031 0.0004 0.4556
n 31 34 Month 36
Mean (SD) –3.86 (3.53) –2.91 (3.11) n 16 15
Median –3.45 –2.50 Mean (SD) –5.08 (4.01) –1.83 (1.40)
P‡ 0.0001 0.0001 0.3434 Median –4.38 –1.87
Last visit P† 0.0001 0.0001 0.0026
n 43 47 Last visit
Mean (SD) –3.39 (3.27) –2.89 (2.98) n 22 21
Median –2.66 –2.41 Mean (SD) –4.07 (3.80) –1.98 (1.50)
P‡ 0.0001 0.0001 0.8463 Median –3.29 –1.87
P† 0.0001 0.0001 0.0449
*Non-parametric analysis of covariance with stratiﬁcation
adjustment for centre and covariance adjustment for baseline *Non-parametric analysis of covariance with covariance
cerebral volume (except baseline comparison, for which the adjustment for baseline cerebral volume (except baseline
Wilcoxon rank sum test was used). †Includes two patients (one comparison, for which the Wilcoxon rank sum test was used).
placebo, one IFNβ-1b) without any post-baseline data. ‡The t test †The t-test was used to assess the signiﬁcance of within-group
was used for signiﬁcance of within-group changes from baseline. changes from baseline.
there was a mean reduction in cerebral volume of 2.91%
compared with baseline. cerebral volume was apparent at 6 months compared with
baseline (P  0.0005) and further reductions were seen There was no signiﬁcant effect of treatment on the
progression of cerebral volume loss at any of the 6-monthly throughout the study, such that by month 36 there was a
mean reduction in cerebral volume of 3.86% compared time points, although there was a trend towards greater
reduction in cerebral volume at 6 months in the treated group with baseline.
In the treated group, a signiﬁcant mean reduction in (P  0.09). Furthermore, the repeated measures analysis of
variance did not show a signiﬁcant treatment effect on cerebral volume of 1.39% was seen at 6 months compared
with baseline (P  0.0001), and further reductions were cerebral volume (P  0.14).
Post hoc analysis was performed by stratifying patients identiﬁed at subsequent time points, such that by month 362260 P. D. Molyneux et al.
Table 4 Percentage change in cerebral volume from
baseline: patients with gadolinium enhancement at baseline
Placebo IFNβ-1b P*
Baseline volume
n 21 25
Mean (SD) 310.74 (25.49) 307.04 (23.46)
Median 321.14 310.36 0.3486
Percentage change in cerebral volume from baseline
Month 6
n 18 22
Mean (SD) –1.09 (0.98) –1.74 (1.53)
Fig. 2 Percentage change in cerebral volume compared with Median –0.86 –1.42
baseline for patients without gadolinium enhancement at baseline. P† 0.0002 0.0001 0.1716
Month 12
n 20 22
Mean (SD) –1.29 (1.40) –2.20 (2.85)
Median –1.51 –1.11
P† 0.0005 0.0016 0.8171
Month 18
n 18 19
Mean (SD) –1.72 (2.43) –2.06 (2.93)
Median –1.45 –1.55
P† 0.0080 0.0066 0.7206
Month 24
n 16 21
Mean (SD) –2.41 (2.79) –2.70 (3.57)
Median –2.20 –1.75
Fig. 3 Percentage change in cerebral volume compared with P† 0.0035 0.0024 0.5961
baseline for patients with gadolinium enhancement at baseline. Month 30
n 14 16
Mean (SD) –1.96 (2.82) –3.41 (4.02) month 36 were 3.7% in the treated subgroup and 2.6% in
Median –2.11 –2.89 the placebo subgroup (P  0.34).
P† 0.0222 0.0040 0.3832
Month 36
n 15 18
Mean (SD) –2.56 (2.44) –3.73 (3.91) Clinical/MRI correlations
Median –2.42 –3.38 Patients with conﬁrmed EDSS progression had a higher rate
P† 0.0011 0.0008 0.3433 of atrophy than those without progression in both treatment
Last visit
groups. In those with conﬁrmed progression, mean percentage n 21 25
reductions in cerebral volume from baseline to month 36 Mean (SD) –2.67 (2.48) –3.59 (3.72)
Median –2.42 –3.38 were 4.95 and 3.31% in the placebo and treated groups,
P† 0.0001 0.0001 0.3277 respectively. In contrast, for patients without progression,
meanpercentagechangeswere2.97and2.56%fortheplacebo *Nonparametric analysis of covariance with covariance
and treated groups, respectively. There was a signiﬁcant but adjustment for baseline cerebral volume (except baseline
low correlation at baseline between EDSS and cerebral comparison, for which the Wilcoxon rank sum test was used).
†The t-test was used to assess the signiﬁcance of within-group volume for the group as a whole (r  –0.18, P  0.018).
changes from baseline. No longitudinal relationship was identiﬁed between the
change in EDSS and the change in cerebral volume. However,
a signiﬁcant relationship between cerebral volume and the into those with and those without gadolinium enhancement
at baseline and subsequently repeating the analysis (Tables 3 composite neuropsychological score at baseline was identiﬁed
for the group as a whole (r  0.25, P  0.007). This and 4, Figs 2 and 3). In the inactive group (no enhancement
at baseline), there was a greater loss of cerebral volume at correlation was signiﬁcant in the placebo group (r  0.30,
P  0.005) but not in the treated group (r  0.15, P 0.18). each time point in the placebo than in the treatment group
(Fig. 2). The mean reductions in cerebral volume in this A signiﬁcant relationship between percentage change in
cerebral volume and the composite neuropsychological group at 36 months were 5.1 and 1.8% for the placebo and
treated subgroups, respectively (P  0.0026); signiﬁcance change score was also identiﬁed for the group as a whole
(r  0.23, P  0.005), which was also signiﬁcant in the was not reached at earlier time points. In the group with one
or more enhancing lesions at baseline, there was a greater placebo group (r  0.32, P  0.002) but not in the treated
group (r  0.14, P  0.31). loss of cerebral volume in the treated than in the placebo
subgroup at all time points (Fig. 3); the mean reductions at There was no difference in the rate of cerebral atrophyCerebral atrophy 2261
between patients who had one or more courses of steroids rate of progressive tissue loss) may have been obscured by the
effect of acute inﬂammatory lesions at baseline. Among the during the study and those who did not (data not shown).
A modest correlation, approaching statistical signiﬁcance, patients with no enhancing lesions at baseline (in whom
relatively few enhancing lesions occurred at follow-up even in was found over the study duration between percentage change
in T2 lesion volume and cerebral volume (r  –0.12, P  the placebo group), there was less cerebral volume reduction
in the treated than in the placebo group at each time point, and 0.098) and between enhancing lesion activity (measured for
months 1–6 and 19–24) and percentage change in cerebral the overall loss of volume in the treated group was less than
half of that seen in the placebo group. In contrast, among the volume (r  –0.15, P  0.059).
patients with at least one enhancing lesion at baseline there
was a trend for the treated group to develop more volume loss
than the placebo group. This may well reﬂect the fact that Discussion
This study documents a decrease in cerebral volume in both IFNβ-1btreatmentisassociatedwithresolutionofoedemaand
inﬂammation in acute multiple sclerosis lesions (Miller et al., treatment groups over a period of 3 years; in contrast to the
effect observed on the clinical parameters, and to a much 1999), resulting in a loss of volume that is not solely due to
ongoing tissue loss (i.e. demyelination or axonal loss). The greater extent the effect on the established MRI parameters
(European Study Group 1999; Miller et al., 1999), there profound effect of IFNβ-1b in reducing the duration of
gadolinium enhancement has been reported recently (Miller was no statistically signiﬁcant effect of treatment on the
development of atrophy. A number of factors might have et al., 1999), indicating that IFNβ-1b treatment facilitates a
more rapid resolution of blood–brain barrier breakdown and contributed to these results.
First, it might be queried whether unblinding of the MRI inﬂammation. This resolution of oedema and acute inﬂam-
matory inﬁltrate due to treatment could have resulted in an analyst could have inﬂuenced the results. This is most
unlikely. The analyst was blinded to the treatment status of apparently greater loss of cerebral volume in the treated than
inthe untreatedgroup. Thismayhave maskedagenuine effect the patients and did not have access to their other imaging
data, such as T2-weighted and gadolinium-enhanced images, of treatment in slowing the rate of ongoing tissue loss in the
cohort as a whole. Such an effect may also have contributed to from which the observation of an apparent treatment effect
might have led to unblinding. The analyst was unblinded to theapparentuncouplingoftherelationshipbetweenthechange
in cerebral volume and the neuropsychological change score the date of the MRI studies; in fact, this was necessary in
order to check for repositioning against the baseline study. in the treated cohort. Furthermore, ongoing enhancing activity
intheplacebogroup,whichwasconsiderableinthosewhohad However, knowledgeof the scandate should nothave affected
the results since the technique is almost fully automated enhancing lesions at baseline, may well have masked the true
extent of atrophy due to progressive tissue loss in this cohort. and is thus not potentially subject to operator-dependent
measurement bias. The average rate of ~1% loss of cerebral Notwithstanding the above caveats, it is likely that most
of the anti-oedema effect of treatment would occur within tissue per year also accords well with that reported in other
studies (Losseff et al., 1996; Fox et al., 2000). the ﬁrst few weeks and months, and it is clear that cerebral
atrophycontinuedtoaccrueinbothtreatmentarmsthroughout Secondly, it is possible that methodological limitations
may have prevented the identiﬁcation of a genuine treatment the whole study period. This is in contrast to the dramatic
and sustained effect of treatment on the well-established effect. This seems unlikely since the technique adopted to
measure cerebral volume has an extremely high level of conventional MRI indices of disease activity (gadolinium
enhancement) and progression (T2 lesion volume). It is, reproducibility, with a scan–rescan variability of 1%
(Losseff et al., 1996). Furthermore, the high level of however, noteworthy that, in terms of magnitude, the results
of treatment on cerebral tissue loss more closely matched automation reduced the risk of operator-dependent
measurement error and measurement drift over time. The the major clinical outcome measure of disability progression.
Thus, disability continued to accrue in the treated group, almost linear reduction in cerebral volume in the placebo
group also suggests that it was detecting genuine change albeit to a signiﬁcantly lesser extent than in the placebo
group, and the results of the current study suggest a trend over time. This supports an earlier study in which signiﬁcant
change in cerebral volume was also demonstrated over towards a modest treatment effect on cerebral atrophy,
although the lower sample size in this analysis might explain 18 months in a smaller cohort of multiple sclerosis patients
(Losseff et al., 1996). why a signiﬁcant treatment effect was seen only with the
clinical endpoints. However, it seems clear that any effect of Thirdly, the study may have been inadequately powered
to detect a treatment effect. Speciﬁc power calculations were treatment on the rate of cerebral tissue loss in this population
of patients would be modest. not performed before the study, as there were insufﬁcient
natural history data obtained with these new techniques to What mechanisms might account for such an ongoing
loss of cerebral tissue in the treated group despite marked allow the estimation of sample size. Furthermore, whereas
95 patients were recruited into the atrophy protocol, only concurrent reduction in acute inﬂammatory lesions? One
possibility is that diffuse tissue atrophy develops in multiple 65 patients had cerebral their volume measured at month 36.
Fourthly, a genuine treatment effect (i.e. a slowing of the sclerosis by mechanisms that are not yet understood but2262 P. D. Molyneux et al.
treatment of multiple sclerosis: ﬁnal outcome of the randomized, which are independent of focal inﬂammatory lesion activity.
controlled trial. Neurology 1995; 45: 1277–85. An alternative explanation is that atrophy is a consequence
of earlier inﬂammatory activity. Recent work has supported Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald
the notion that the acute inﬂammatory process may result in WI, et al. Progressive cerebral atrophy in multiple sclerosis. A serial
an inevitable pathological cascade, with demyelination and MRI study. Brain 1996; 119: 2009–19.
axonal loss as the end result (Coles et al., 1999; Paollilo Miller DH, Grossman RI, Reingold SC, McFarland HF. The role
et al., 1999, Simon et al., 1999). Treatment aimed at of magnetic resonance techniques in understanding and managing
preventing the formation of further new lesions may have multiple sclerosis. [Review]. Brain 1998; 121: 3–24.
little effect on this process, once established. That atrophy
Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, can occur in the face of minimal inﬂammatory multiple
Wagner K. Effect of interferon-beta 1b on magnetic resonance sclerosis lesion activity is also suggested by studies in
imaging outcomes in secondary progressive multiple sclerosis:
primary progressive multiple sclerosis, in which gadolinium results of a European multicenter, randomized, double-blind,
enhancement is relatively infrequent, but substantial atrophy placebo-controlled trial. Ann Neurol 1999; 46: 850–9.
nonetheless occurs in the brain (Filippi et al., 1999; Stevenson
Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, et al., 2000; Tortorella et al., 2000). It is therefore possible
Truyen L, et al. Correlations between monthly enhanced MRI lesion that IFNβ-1b will have a greater effect in slowing the
rate and changes in T2 lesion volume in multiple sclerosis. [Review]. progression of atrophy if given earlier in the disease course. Ann Neurol 1998; 43: 332–9.
It is of interest that IFNβ-1a has been reported to slow the
Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus progression of atrophy in a group of patients with RR multiple
D, Barker GJ, et al. Quantitative MRI in patients with secondary sclerosis and minimal disability, although this effect was
progressive MS treated with monoclonal antibody Campath 1H. only marginally signiﬁcant and then only in the second year
Neurology 1999; 53: 751–7. of treatment (Rudick et al., 1999). Also, the cohort studied
Paty DW, Li DK, the UBC MS/MRI Study Group and the IFNβ was larger than in the present study, increasing the likelihood
Multiple Sclerosis Study Group. Interferon beta-1b is effective in of demonstrating statistical signiﬁcance, and the methods for
relapsing–remitting multiple sclerosis. II. MRI analysis results of quantifying atrophy were not the same as in the current
a multicenter, randomized, double-blind, placebo-controlled trial. study. Further work is therefore needed both to elucidate the
Neurology 1993; 43: 662–7. mechanisms by which atrophy develops at different stages
Polman C, Dahlke F, Thompson AJ, Ghazi M, Kappos L, of the disease and to determine whether the effect of IFNβ
Miltenburger C, et al. Interferon beta-1b in secondary progressive treatment on atrophy progression at the various stages of the
multiple sclerosis-outline of the clinical trial. Mult Scler 1995; 1: disease is indeed different.
S51–54.
PRISMS (Prevention of Relapses and Disability by Interferon beta-
1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised
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